Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β3-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction

BJU International

Volumn 110, Issue , 2012, Pages

  Gillespie, James I ^a,b   Palea, Stefano ^d   Guilloteau, Veronique ^d   Guerard, Marc ^d   Lluel, Philippe ^d   Korstanje, Cees ^c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Astellas Pharma Global Development   (Netherlands)

^d UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

chronic urethral obstruction; mirabegron; non voiding activity; rat; tolterodine

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; MIRABEGRON; MUSCARINIC RECEPTOR BLOCKING AGENT; TOLTERODINE;

ADRENERGIC TRANSMISSION; AMPLITUDE MODULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CONTRACTION; BLADDER FILLING; BLADDER NECK STENOSIS; BLADDER WALL; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; CYSTOMETRY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; FEMALE; MICTURITION; MOTOR SYSTEM; NONHUMAN; ORGAN WEIGHT; OVERACTIVE BLADDER; PRIORITY JOURNAL; RAT; SENSORY SYSTEM; SINGLE DRUG DOSE; TREATMENT DURATION; URINARY FREQUENCY; URODYNAMICS;

ACETANILIDES; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ANIMALS; BENZHYDRYL COMPOUNDS; CRESOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INFUSIONS, INTRAVENOUS; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLES; URINARY BLADDER NECK OBSTRUCTION; URINARY BLADDER, OVERACTIVE; URINATION;

EID: 84863551967     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11240.x     Document Type: Article

References (38)

1. Abrams P, Cardozo L, Fall M, et al,. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78
2. Digesu GA, Khullar V, Cardozo L, Salvatore S,. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 2003; 22: 105-8
3. Malmgren A, Sjögren C, Uvelius B, et al,. Cystometric evaluation of bladder instability in rats with infravesical outflow obstruction. J Urol 1987; 137: 1291-994
4. Lluel P, Duquenne C, Martin D,. Experimental bladder instability following bladder outlet obstruction in the female rat. J Urol 1998; 160: 2253-7
5. Kaiho Y, Nishiguchi J, Kwon DD, et al,. The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction. BJU Int 2007; 101: 615-20
6. Wojdan A, Freeden C, Woods M, et al,. Comparison of the potassium channel openers, WAY-133537, ZD6169, and celikalim on isolated bladder tissue and in vivo bladder instability in rat. J Pharmacol Exp Ther 1999; 289: 1410-8
7. Nurse DE, Restorick JM, Mundy AR,. The effect of chromakalim on the normal and hyper-reflexic human detrusor muscle. Br J Urol 1991; 68 (Suppl. 1): 27-31
8. Martin SW, Radley SC, Chess-Williams R, et al,. Relaxant effects of potassium-channel openers on normal and hyper-reflexic detrusor muscle. Br J Urol 1997; 80: 405-13
9. Oger S, Behr-Roussel D, Gorny D, et al,. Suppression of phasic contractile activity of human detrusor strips by cyclic nucleotide Phosphodiesterase type 4 inhibition. Eur Urol 2007; 51: 772-80
10. 3-adrenoceptor agonist in patients with overactive bladder (OAB). Eur Urol 2010; 9 (Suppl.): 249
11. Nitti V, Herschorn S, Auerbach S, et al,. The efficacy and safety of mirabegron in patients with overactive bladder syndrome-results from a North-American Phase III trial. Presented at the 26th Annual Congress of the European Association of Urology, Vienna, Austria, 18-22 March 2011
12. Khullar V, Cambronero J, Stroberg P, et al,. The efficacy and tolerability of mirabegron in patients with overactive bladder-results from a European-Australian Phase III trial. Presented at the 26th Annual Congress of the European Association of Urology, Vienna, Austria, 18-22 March 2011
13. Drake MJ, Fowler CJ, Griffiths D, et al,. Neural control of the lower urinary and gastrointestinal tracts: supraspinal CNS mechanisms. Neurourol Urodyn 2010; 29: 119-27
14. 3- adrenoceptor-mediated relaxation of the human detrusor. Acta Physiol Scand 1998; 164: 117-8
15. 3- adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 1999; 288: 1367-73
16. Igawa Y, Yamazaki Y, Takeda H, et al,. Relaxant effects of isoproterenol and selective β3-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders. J Urol 2001; 165: 240-4
17. 3-adrenoceptors in human and rat detrusor muscle. J Urol 1999; 161: 680-5
18. Takeda H, Yamazaki Y, Akahane M, et al,. Role of the β3-adrenoceptor in urine storage in the rat: comparison between the selective β3-adrenoceptor agonist, CL316,243, and various smooth muscle relaxants. J Pharmacol Exp Ther 2000; 293: 939-45
19. Woods M, Carson N, Norton NW, et al,. Efficacy of the β3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol 2001; 166: 1142-7
20. Takeda H, Yamazaki Y, Igawa Y, et al,. Effect of β3-adrenoceptor stimulation on prostaglandin E2-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol Urodyn 2002; 21: 558-65
21. Takasu T, Ukai M, Sato S, et al,. Effect of (R)-2-(2-aminothiazol-4-yl)- 4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 2007; 321: 642-7
22. Streng T, Hedlund P, Talo A, et al,. Phasic non-micturition contractions in the bladder of the anaesthetised and awake rat. BJU Int 2006; 97: 1094-101
23. Starling EH,. Elements of Human Physiology, 7th edn. London: Churchill, 1905
24. Iggo A,. Tension receptors in the stomach and urinary bladder. J Physiol 1955; 128: 593-607
25. Vaughan CW, Satchell PM,. Urine storage mechanisms. Prog Neurobiol 1995; 46: 215-37
26. Gillespie JI,. The autonomous bladder: a view of the origin of bladder overactivity. BJU Int 2004; 93: 478-83
27. Gillespie JI, Van Koeveringe GA, De Wachter SG, et al,. On the origins of the sensory output from the bladder: the concept of afferent noise. BJU Int 2009; 103: 1324-33
28. Bristow SE, Neal DE,. Ambulatory urodynamics. Br J Urol 1996; 77: 333-8
29. Fowler CJ, Griffiths D, de Groat WC,. The neural control of micturition. Nat Rev Neurosci 2008; 9: 453-66
30. Drake MJ, Hedlund P, Harvey IJ, et al,. Partial outlet obstruction enhances modular autonomous activity in the isolated rat bladder. J Urol 2003; 170: 276-9
31. Igawa Y, Mattiasson A, Andersson K-E,. Micturition and premicturition contractions in unanethetized rats with bladder outlet obstruction. J Urol 1994; 151: 244-9
32. Gjone R,. Peripheral autonomic influence on the motility of the urinary bladder in the cat. I. Rhythmic contractions. Acta Physiol Scand 1965; 65: 370-7
33. Vaughan CW, Satchell PM,. Role of sympathetic innervation in the feline continence process under natural filling conditions. J Neurophysiol 1992; 68: 1842-9
34. Gillespie JI,. Noradrenaline inhibits autonomous activity in the isolated guinea pig bladder. BJU Int 2004; 93: 401-9
35. de Jongh R, van Koeveringe GA, van Kerrebroeck PE, et al,. Damage to the bladder neck alters autonomous activity and its sensitivity to cholinergic agonists. BJU Int 2007; 100: 919-29
36. Iijima K, De Wachter S, Wyndaele JJ,. Effects of the M3 receptor selective muscarine antagonist darifenacin on bladder efferent activity of the rat pelvic nerve. Eur Urol 2007; 52: 842-9
37. 2 on the primary bladder afferent activity of the rat. Neurourol Urodyn 2010; 29: 771-6
38. Birder LA,. Urothelial signalling. Handb Exp Pharmacol 2011; 207: 21290228